Skip to main content
. Author manuscript; available in PMC: 2019 Oct 15.
Published in final edited form as: Clin Cancer Res. 2018 May 16;24(20):4921–4930. doi: 10.1158/1078-0432.CCR-18-0246

Figure 2.

Figure 2

Comparative performances of the time-to-event Bayesian optimal interval (TITE-BOIN), rolling six (R6), and time-to-event continual reassessment method (TITE-CRM) designs with respect to that of the 3+3 design. (a and b) Relative percentages of correct selection (PCS) of the MTD; (c and d) Relative percentages of patients assigned to the MTD. The target DLT rate in scenarios 1-8 is 0.2, while that in scenarios 9-16 is 0.3. The accrual rate is 2 patients/month. A higher value is better.